Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBI-8000 in Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma
NCT02955589Phase 2Completed
- Sponsor
- HUYABIO International, LLC
- Start
- Nov 2016
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat in adult T-cell leukemia-lymphoma (ATLL), sponsored by HUYABIO International, LLC. Primary endpoint: Objective Response Rate up to 15 months. Started Nov 2016; status: completed.
02
Drugs
tucidinostat
03
Conditions
adult T-cell leukemia-lymphoma (ATLL)
Beyond the preview
Go deeper on NCT02955589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02955589.